http://www.vanleeuwenhoeckresearch.com/(c) 2009, Van Leeuwenhoeck Research All rights reserved.5You can subscribe to this RSS Feed to keep updated on the latest articles on Van Leeuwenhoeck Research.Dutch/Danish biotech company Genmab saw a strong rebound in its share price of more than 50% from a low of DKK 40. The primary reason for this in our opinion was due to the outcome of a renegotiated partnership with GSK on Arzerra. This provides Genmab with a upfront payment of STG 90 million. The payment is inclusive of the reduced R&D expenses for Genmab on Arzerra, giving Genmab much needed financial stability and also the first sign towards earning back its investors trust. More to follow.http://www.vanleeuwenhoeck.com/article/europe/genmab-restoring-confidence.htmSat, 24 Jul 2010 10:56:00 GMTSat, 31 Jul 2010 12:10:09 GMTThere are rising problems with bacteria becoming resistant against antibiotics. MRSA is especially troublesome in hospitals, where patients with open wounds, invasive devices and weakened immune systems are at greater risk of infection than the general public. However, the is possibly a treatment for both preventing and treating diffi cult to treat infections like MRSA in a far more cheaper and effective way than vaccines or the current failing antibiotics. That answer might me a revived remedy: phage therapy.http://www.vanleeuwenhoeck.com/article/europe/the-battle-for-bacteria-antibiotics-versus-phage-therapy.htmWed, 21 Jul 2010 22:13:00 GMTSat, 31 Jul 2010 12:10:09 GMTVLR Expands into United States with Financial Research Platform for Life Sciences Companieshttp://www.vanleeuwenhoeck.com/article/financial/vlr-opens-office-in-nyc.htmWed, 07 Apr 2010 11:09:00 GMTSat, 31 Jul 2010 12:10:09 GMThttp://www.vanleeuwenhoeck.com/article/europe/galapagos-hidden-gem-in-european-biotech.htmSun, 28 Feb 2010 02:50:00 GMTSat, 31 Jul 2010 12:10:09 GMThttp://www.vanleeuwenhoeck.com/article/europe/crucell-from-prey-to-predator-.htmSun, 28 Feb 2010 02:49:00 GMTSat, 31 Jul 2010 12:10:09 GMThttp://www.vanleeuwenhoeck.com/article/europe/scenario-s-for-genmab-in-2010.htmSun, 28 Feb 2010 02:47:00 GMTSat, 31 Jul 2010 12:10:09 GMThttp://www.vanleeuwenhoeck.com/article/us/cuts-in-rd-pharma-bodes-well-for-biotech.htmSun, 28 Feb 2010 02:45:00 GMTSat, 31 Jul 2010 12:10:09 GMThttp://www.vanleeuwenhoeck.com/article/europe/neurosearch-concludes-positive-phase-iii-results-in-huntington-s-disease.htmSun, 28 Feb 2010 02:42:00 GMTSat, 31 Jul 2010 12:10:09 GMTOver 6,000 people piled into the Westin St. Francis Hotel in San Francisco for J.P. Morgan’s (JPM) “28th Annual Healthcare Conference.” Investors, company presenters, and entrepreneurs were emboldened by good biotech sector returns in 2009 of 18–28% with many stocks reaching new highs. Seasonality has been a factor with the so-called “January effect,” where small-cap stocks tend to spike for a number of reasons, this conference paramount among them. For example, the IBB ETF is up about 6% from November levels. Following are some brief notes from important companies presenting at JPM.http://www.vanleeuwenhoeck.com/article/us/reporting-from-j-p-morgan-healthcare-conference.htmSun, 17 Jan 2010 22:49:00 GMTSat, 31 Jul 2010 12:10:09 GMTAt the 28th annual JP Morgan Healthcare conference, which ran from January 11- January 14th 2010, there were more than 300 companies represented, making their presentations to more than 6000 public and private equity and venture capital investors. There was considerable enthusiasm for the sector this past week; it seemed like every biotech company rallied and closed the week up. But what will happen after the JP Morgan Healthcare Conference? Was the activity the last couple weeks just due to short term investor enthusiasm? http://www.vanleeuwenhoeck.com/article/us/the-future-of-biotech-party-likes-its-1999.htmSun, 17 Jan 2010 22:19:00 GMTSat, 31 Jul 2010 12:10:09 GMTOne of the best performing European biotech companies in 2009 was Swedish biotech company Active Biotech. With a performance of more than 200% the stock was one of the top 3 best performing Biotech companies. And also in 2010 the company seems to continue its winning streak with a YTD performance of already 35%. What is the story behind this amazing performance.http://www.vanleeuwenhoeck.com/article/europe/active-biotech-continues-winning-streak.htmSun, 10 Jan 2010 20:06:00 GMTSat, 31 Jul 2010 12:10:09 GMTThey say aging is one of the few certain things in life. But it turns out that they were wrong. In recent years gerontologists have overturned much of the conventional wisdom about getting old. Aging is not the simple result of the passage of time. According to a provocative new view, it is actually something our own bodies create, a side effect of the essential inflammatory system that protects us against infectious disease. As we fight off invaders, we inflict massive collateral damage on ourselves, poisoning our own organs and breaking down our own tissues. We are our own worst enemy. http://www.vanleeuwenhoeck.com/article/us/can-we-cure-aging.htmThu, 22 Oct 2009 22:38:00 GMTSat, 31 Jul 2010 12:10:09 GMTA video showing what to expect from the Swine Flu and what companies will profithttp://www.vanleeuwenhoeck.com/article/us/video-swine-flu-expectations.htmMon, 14 Sep 2009 02:07:00 GMTSat, 31 Jul 2010 12:10:09 GMTGenetics is continuing to revolutionize medicine, and is throwing up some exciting investment opportunities. Especially in stem cell research.http://www.vanleeuwenhoeck.com/article/europe/how-to-profit-from-medical-breakthroughs.htmSun, 13 Sep 2009 15:39:00 GMTSat, 31 Jul 2010 12:10:09 GMTInvestors are placing final bets on upcoming late-stage trial data from Osiris Therapeutics. The company's Prochymal is being tested as a treatment for GvHD, a potentially deadly complication of bone marrow transfusionshttp://www.vanleeuwenhoeck.com/article/us/stem-cell-data-jitters-could-presage-big-gains.htmSun, 06 Sep 2009 20:40:00 GMTSat, 31 Jul 2010 12:10:09 GMT